OcuSciences, Inc., received U.S. Food and Drug Administration (FDA) clearance for its OcuMet Beacon, a proprietary, confocal scanning ophthalmoscope indicated for infrared and autofluorescence retinal imaging with or without a mydriatic agent. The device uses proprietary illumination and detection technology and software to aid in visualizing the functional image signature, according to a press release. Visit www.ocusciences.com. Source: Optometric Management
